Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegobuvir and GS-9256 in Chronic HCV Genotype 1
NCT01225380Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2010
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in hepatitis C (HCV) comparing GS-9190 + GS-9256 + SOC, GS-9256 + SOC and Placebo Control (3 arms). Primary endpoint: Sustained Virologic Response 24 weeks after treatment cessation. Started Oct 2010; status: completed.
02
Drugs
tegobuvirGS-9256
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01225380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01225380.